TY - JOUR T1 - Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan JF - medRxiv DO - 10.1101/2021.06.16.21258673 SP - 2021.06.16.21258673 AU - Qianyun Liu AU - Qing Xiong AU - Fanghua Mei AU - Chengbao Ma AU - Zhen Zhang AU - Bing Hu AU - Junqiang Xu AU - Yongzhong Jiang AU - Faxian Zhan AU - Xianying Chen AU - Ming Guo AU - Xin Wang AU - Yaohui Fang AU - Shu Shen AU - Yingle Liu AU - Fang Liu AU - Li Zhou AU - Ke Xu AU - Changwen Ke AU - Fei Deng AU - Kun Cai AU - Huan Yan AU - Yu Chen AU - Ke Lan Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/21/2021.06.16.21258673.abstract N2 - Most COVID-19 patients can build effective humoral immunity against SARS-CoV-2 after recovery(1, 2). However, it remains unknown how long the protection can maintain and how efficiently it can protect people from the reinfection of the emerging SARS-CoV-2 variants. Here we evaluated the sera from 248 COVID-19 convalescents around one year post-infection in Wuhan, the earliest epicenter of SARS-CoV-2. We demonstrated that the SARS-CoV-2 immunoglobulin G (IgG) maintains at a high level and potently neutralizes the infection of the original strain (WT) and the B.1.1.7 variant in most patients. However, they showed varying degrees of efficacy reduction against the other variants of concern (P.1, B.1.525, and especially B.1.351) in a patient-specific manner. Mutations in RBD including K417N, E484K, and E484Q/L452R (B.1.617) remarkably impair the neutralizing activity of the convalescents’ sera. Encouragingly, we found that a small fraction of patients’ sera showed broad neutralization potency to multiple variants and mutants, suggesting the existence of broadly neutralizing antibodies recognizing the epitopes beyond the mutation sites. Our results suggest that the SARS-CoV-2 vaccination effectiveness relies more on the timely re-administration of the epitope-updated vaccine than the durability of the neutralizing antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the National Science and Technology Major Project (2018YFA0900801), China NSFC projects (32041007 and 32070160), Fundamental Research Funds for the Central Universities (2042021kf0220 and 2042020kf0024), the Advanced Customer Cultivation Project of Wuhan National Biosafety Laboratory (2021ACCP-MS10) and Special Fund for COVID-19 Research of Wuhan University. We are grateful to Beijing Taikang Yicai Foundation for their great support to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All blood donors provided written informed consent for participation in the study. These human sera protocols were approved by the Ethics Committee of Hubei Provincial Center for Disease Control and Prevention, Wuhan, China (No. 2021-012-01)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or extended data. ER -